Top 5 Net Payout Yield Stocks To Invest In Right Now


And the third time is the charm.

AFP

On Monday, the Dow Jones Industrial Average broke 16,000 for the first time ever, only to finish the day under that big round number. On Tuesday, it tried again, but dropped at the end of the day. And after yesterday’s drop, 16,000 looked farther away than ever. But all it took was a little economic data in the form of jobless claims  to push the Dow Jones over 16,000, this time to stay. The blue-chip index gained 0.7% to 16,009.99, while the S&P 500 rose 0.8% to 1,795.86.


JPMorgan Chase (JPM) and American Express (AXP) rose 2% and 2.1%, respectively, as financial stocks gained on speculation that the jobless claims data would spur the Federal Reserve to taper sooner rather than later, while Ace Ltd. (ACE) rose 3.8%.  General Motors (GM) gained 1.1% after the US government said it could sell the last of its shares by year-end. On the downside, Target (TGT) fell 3.5% after reporting earnings that missed analyst expectations.

Top 5 Net Payout Yield Stocks To Invest In Right Now: Westfield Financial Inc.(WFD)

Westfield Financial, Inc. operates as a bank holding company for the Westfield Bank that provides various community banking products and services to businesses and individuals in Massachusetts. The company offers various deposit products, including regular savings deposits comprising passbook and statement savings accounts; NOW accounts; noninterest-bearing demand accounts; money market accounts; certificates of deposit; and time deposits. Its loan portfolio primarily consists of commercial and industrial loans, such as business installment loans, vehicle and equipment financing, lines of credit, and other commercial loans; commercial real estate loans to finance the purchase of real property, and construction loans to developers of commercial and residential properties; residential real estate loans; home equity loans; and consumer loans that consist of automobile loans, secured passbook loans, credit lines tied to deposit accounts to provide overdraft protection, and uns ecured personal loans. The company also offers commercial products and services, which include commercial deposit accounts, cash management services, Internet banking, sweep accounts, ATM network, remote deposit, and night deposit services. It operates 11 banking offices in Agawam, East Longmeadow, Holyoke, Southwick, Springfield, West Springfield, and Westfield, Massachusetts; and 12 free-standing ATM locations in Feeding Hills, Holyoke, Springfield, West Springfield, and Westfield, Massachusetts. The company was founded in 1853 and is based in Westfield, Massachusetts.


Advisors’ Opinion:

  • [By Tim Melvin]

    Westfield Financial (WFD) has 11 branches and about $1.3 billion in total assets in Massachusetts. The company has been consistently buying back its shares and in September authorized another 5% stock buyback plan. In the fourth quarter alone the bank repurchased 603,046 shares of its stock at below book value. In addition to the buyback, the bank pays a generous dividend — 3.22% at the current price.

  • [By Dividends4Life]

    Memberships and Peers: PBCT is a member of the S&P 500 and a member of the Broad Dividend Achievers™ Index. The company’s peer group includes: Bank of America Corporation (BAC) with a 0.3% yield, Brookline Bancorp, Inc. (BRKL) with a 3.7% yield and Westfield Financial Inc. (WFD) with a 3.5% yield.

Top 5 Net Payout Yield Stocks To Invest In Right Now: Titan Pharmaceuticals Inc (TTNP.OB)


Titan Pharmaceuticals, Inc., incorporated in February 1992, is a biopharmaceutical company developing therapeutics primarily for the treatment of central nervous system (CNS) disorders. The Company is focused primarily on clinical development of products that include Probuphine for the treatment of opioid addiction; Iloperidone: for the treatment of schizophrenia and related psychotic disorders, and Spheramine for the treatment of advanced Parkinson’s disease. Titan Pharmaceuticals is directly developing its product candidates and also utilizing corporate partnerships, including a collaboration with Bayer Schering Pharma AG, Germany (Bayer Schering) for the development of Spheramine to treat Parkinson’s disease, and Vanda Pharmaceuticals, Inc. (Vanda) for the development of iloperidone for the treatment of schizophrenia and related psychotic disorders.


Probuphine

Probuphine is the first product to utilize the Company’s ProNeura long-ter m drug delivery technology. Probuphine is designed to provide continuous, long-term therapeutic levels of the drug buprenorphine, an approved agent for the treatment of opioid addiction. In December 2007, the Company completed enrollment in a randomized, double-blind, placebo-controlled, multi-center Phase III clinical study of Probuphine in the treatment of opioid addiction. This 150 patient study, which is being conducted in the United States, will evaluate the safety and effectiveness of treatment with Probuphine versus placebo in reducing opioid addiction over 24 weeks of treatment. This study is part of a registration directed program intended to obtain marketing approval of Probuphine for the treatment of opioid addiction in Europe and the United States.


Iloperidone

Iloperidone was evaluated in a Phase III program comprising over 3,500 patients at more than 200 sites in 24 countries, administered and funded by Novartis Pharma AG (Novartis). In three completed efficacy studies conducted by Novartis, ! i! loperidone statistically reduced the symptoms of schizophrenia compared to placebo. Iloperidone has also been investigated in three 12-month safety studies, which confirm safety and tolerability. A dose dependent increase in the Q-T Corrected (QTc) interval was observed and investigated further in a clinical study, and no clinically significant adverse events were observed. In September 2007, Vanda submitted a new drug application (NDA) with the United States Food and Drug Administration (FDA) for iloperidone. The NDA for iloperidone was officially accepted for review by the FDA in November 2007.


Spheramine

Spheramine is a cell-based therapeutic that utilizes the Company’s cell-coated microcarrier (CCM) technology, which enables the development of cell-based therapies for minimally invasive, site-specific delivery to the central nervous system of therapeutic factors precisely where they are needed. Spheramine consists of microcarriers coated wit h human retinal pigment epithelial cells that are intended to enhance brain levels of dopamine, a neurotransmitter deficient in certain brain regions in Parkinson’s disease, leading to movement disorders. Preclinical studies have demonstrated the preliminary efficacy and safety of Spheramine, including blinded studies in a primate model of Parkinson’s disease. In June 2007, enrollment was completed in a current multi-center, randomized, double-blind, placebo-controlled clinical trial of Spheramine in Parkinson’s disease. This Phase IIb clinical study enrolled 71 patients with advanced Parkinson’s disease (Hoehn and Yahr Stages III and IV) to further evaluate the efficacy, safety, and tolerability of Spheramine.


Bayer Schering, the Company’s corporate partner for worldwide development and commercialization of Spheramine, is funding the clinical development program for Spheramine. Under an agreement, Bayer Schering has received exclusive, worldwide deve lopment, manufacturing and commercialization rights, an! d, in! ad! dition! to the clinical and manufacturing development funding and milestone payments, Bayer Schering will pay Titan Pharmaceuticals a royalty on future product sales.

Advisors’ Opinion:

  • [By C.R. Jackson]

    Fanapt was discovered by Hoechst Marion Roussel in 1995 as a novel atypical antipsychotic agent. Hoechst was a German life-sciences company that became Aventis Deutschland after its merger with France’s Rhône-Poulenc in 1999. When the company joined with Sanofi-Synthélabo in 2004, it became a subsidiary of the Sanofi-Aventis (SNY) the French pharmaceutical conglomerate. In 1997, Hoechst sold the research rights to Titan Pharmaceuticals (TTNP.OB). Then Titan quickly sold the worldwide rights to Novartis in 1998. Novartis then sold the Phase 3 development rights for loperidone to Vanda in 2004. Vanda originally attempted to get FDA approval for Fanapt in 2008, but the FDA refused to approve iloperidone. The agency required an additional clinical trial.

Top 5 Net Payout Yield Stocks To Invest In Right Now: Safran SA (SAFRY.PK)


Safran SA is a France-based high-technology company which produces aircraft and rocket engines and propulsion systems. It divides its work into three segments: Aerospace, Aircraft, Defense and Security. The Aerospace Propulsion division provides engines, turbines and parts for aircraft, and rocket boosters for civil, military and spatial markets through several subsidiaries, including Snecma, among others. The Aircraft Equipment division produces landing gear, wheels and carbon brakes, aircraft engine nacelles and airborne power electronics through its subsidiaries, including Aircelle, among others. The Defense division includes the subsidiary, Sagem, and makes systems and equipment for inertial navigation and other defense applications to be used on military transport and combat aircraft, helicopters, warships, armored vehicles and artillery systems. In October 2013, the Company completed the sale of its United States-based subsidiary, Global Motors Inc to Allied Motion Inc. Advisors’ Opinion:

  • [By Daniel Lauchheimer]

    Currently, three main companies supply security equipment to the TSA – Safran (SAFRY.PK), Smiths (SMGKF.PK), and Level-3 Holdings (LLL). All three of these companies sell the whole range of their products to the TSA, with an ETD offering included. Recently, however, a new company, Implant Sciences Corporation (IMSC.PK) received approval from the TSA to begin selling their ETD equipment to airport security professionals. This approval has opened the door for IMSC to begin taking some market share away from the more established players in the US and beyond.

Top 5 Net Payout Yield Stocks To Invest In Right Now: LDK Solar Co. Ltd.(LDK)


LDK Solar Co., Ltd., together with its subsidiaries, engages in the design, development, manufacture, and marketing of photovoltaic (PV) products; and development of power plant projects. It offers solar-grade and semiconductor-grade polysilicon; and multicrystalline and monocrystalline solar wafers to the manufacturers of solar cells and solar modules. The company also provides wafer processing services to monocrystalline and multicrystalline solar cell and module manufacturers; and sells silicon materials, such as ingots and polysilicon scraps. In addition, it engages in the production and sale of solar cells and modules to developers, distributors, and system integrators; and design and development of solar power projects in Europe, the United States, and China, as well as provides engineering, procurement, and construction services. LDK Solar Co., Ltd. operates in Europe, the Asia Pacific, and North America. The company was founded in 2005 and is based in Xinyu City, t he People?s Republic of China.


Advisors’ Opinion:

  • [By Aaron Levitt]

    Both Suntech and Chaori Solar have already filed, while LDK (LDK) is in the process of doing so and delisting from the NYSE.

    All of this negative activity doesn’t inspire a whole lot of confidence in Chinese solar stocks. For investors, the best course of action could be to bail on the sector completely or at least move out of individual names and into a broad play like the TAN or Market Vectors Solar Energy ETF (KWT).

  • [By Jonathan Yates]

    For investors looking to profit from shorting stocks in the sector, JA Solar Holdings (NASDAQ: JASO) and LDK Solar (NYSE: LDK) are both vulnerable. For those looking to go long, Exxon Mobil (NYSE: XOM) is very strong in natural gas, which is expected to increase its market share, according to a recent report from the Department of Energy.

Top 5 Net Payout Yield Stocks To Invest In Right Now: Aluminum Corporation of China Ltd(ACH)


Aluminum Corporation of China Limited engages in the manufacture and distribution of alumina, primary aluminum, and aluminum fabrication products in the People?s Republic of China and internationally. Its Alumina segment involves in the mining and purchasing of bauxite and other raw materials, refining of bauxite into alumina, and sale of alumina. This segment also produces and sells chemical alumina, including alumina hydroxide and alumina chemicals, and metal gallium. The company?s Primary Aluminum segment engages in smelting alumina to produce primary aluminum, principally ingots for use in general aluminum fabrication in the construction, power generation, automobile, packaging, machinery, and durable goods industries. This segment also produces and sells carbon products and aluminum alloy products. The Aluminum Fabrication segment involves in the production and sale of aluminum fabrication products, including casts, planks, screens, extrusions, forges, powder, and die castings for use in the construction, power generation, automobile, packaging, machinery, and durable goods industries. The Trading segment engages in the procurement and sale of alumina, primary aluminum, and aluminum fabrication products, as well as relevant metal products, and raw and ancillary materials. The company also engages in the manufacture and distribution of metal materials; sale of general machinery and equipment; production, acquisition, and distribution of limestone ore, aluminum magnesium ore, and related nonferrous metal products; aluminum smelting, manufacture, and distribution of nonferrous metals; and generation and supply of electricity, as well as in iron ore mining and coal mining activities. Aluminum Corporation of China Limited was founded in 2001 and is based in Beijing, China.


Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    During the quarter, Visa (V) reported strong year-­‐over-­‐year growth with earnings up 14%, as the business continues to operate at a superior level – very much in-­‐line with the past several years. Visa has been a core holding for our clients since October 2008 and rarely has a year gone by without the Company and its partners having to contend with lawsuits and legislation aimed at limiting pricing power and 4 distribution. 2014 is no exception, though most of the news has been favorable, with a ruling for “no change” to Visa’s exclusivity for high-­‐value signature transactions. We continue to see Visa’s pricing power as being derived from VisaNet’s superior value proposition relative to substitutes, particularly paper-­‐ based payments, automated clearinghouse (ACH), and more recently, “cryptocurrencies” (e.g. Bitcoin). While these emerging payment platforms, including PayPal and Square, represent very legitimate substitutes to traditional interchan ge, in our view they are not quite “good enough,” as evidenced by merchant acceptance that is largely sequestered to small businesses. While we have been net sellers of Visa over the past 18 months, it has been solely due to valuation – our primary tool for risk management at Wedgewood. We believe Visa will continue to maintain its superior competitive positioning, as competitors find it difficult to achieve the network-­‐effect benefits that have compounded the value proposition of VisaNet, particularly as acceptance and issuance of the Visa brand continues to expand.From David Rolfe (Trades, Portfolio)’s Wedgewood Partners first quarter 2014 commentary.
    Also check out: David Rolfe Undervalued Stocks David Rolfe Top Growth Companies David Rolfe High Yield stocks, and Stocks that David Rolfe keeps buying
    Currently 0.00/512345


    Rating: 0.0/5 (0 votes)

  • [By Holly LaFon]

    During the quarter, Visa (V) reported strong year-­‐over-­‐year growth with earnings up 14%, as the business continues to operate at a superior level – very much in-­‐line with the past several years. Visa has been a core holding for our clients since October 2008 and rarely has a year gone by without the Company and its partners having to contend with lawsuits and legislation aimed at limiting pricing power and 4 distribution. 2014 is no exception, though most of the news has been favorable, with a ruling for “no change” to Visa’s exclusivity for high-­‐value signature transactions. We continue to see Visa’s pricing power as being derived from VisaNet’s superior value proposition relative to substitutes, particularly paper-­‐ based payments, automated clearinghouse (ACH), and more recently, “cryptocurrencies” (e.g. Bitcoin). While these emerging payment platforms, including PayPal and Square, represent very legitimate substitutes to traditional interchang e, in our view they are not quite “good enough,” as evidenced by merchant acceptance that is largely sequestered to small businesses. While we have been net sellers of Visa over the past 18 months, it has been solely due to valuation – our primary tool for risk management at Wedgewood. We believe Visa will continue to maintain its superior competitive positioning, as competitors find it difficult to achieve the network-­‐effect benefits that have compounded the value proposition of VisaNet, particularly as acceptance and issuance of the Visa brand continues to expand.

  • [By Patricio Kehoe]

    With respect to the auto industry, vehicle sales are high in the last 12 months. But looking forward, Aluminum represents the second largest-volume component material in automotive vehicles and is expected to double by 2025. The firm’s largest competitor includes Aluminum Corporation of China Limited (ACH). Hedge fund gurus have also been active in the company. Gurus like Steven Cohen (Trades, Portfolio), Mario Gabelli (Trades, Portfolio), Paul Tudor Jones (Trades, Portfolio) and First Pacific Advisors (Trades, Portfolio) have added it in fourth quarter 2013.

  • [By Louis Navellier]

    However, don’t be fooled into thinking AA is a good buy right now: This company falls short on sales growth. Alcoa’s main competitor is Aluminum Corporation of China Ltd. (ACH), but it is also rated a sell. So I wouldn’t be looking for buying opportunities in aluminum right now.